ACVR1: Difference between revisions
CSV import |
CSV import |
||
| Line 21: | Line 21: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 02:48, 17 March 2025
ACVR1 is a human gene that encodes for the protein Activin A receptor type 1. This protein is a member of the protein kinase superfamily and the TGFB receptor subfamily. The encoded protein is a transmembrane serine/threonine kinase that is found in various tissues and cell types. It plays a crucial role in bone growth and development, and mutations in this gene are associated with the rare genetic disorder Fibrodysplasia Ossificans Progressiva (FOP).
Structure[edit]
The ACVR1 gene is located on the long (q) arm of chromosome 2 at position 24. The gene spans approximately 58,000 base pairs and consists of 11 exons. The encoded protein is a type I receptor with a molecular weight of approximately 53 kDa. It contains a glycosylation site, a transmembrane domain, a GS domain, and a serine/threonine kinase domain.
Function[edit]
ACVR1 is a receptor for members of the transforming growth factor-beta (TGF-beta) family, such as activin and bone morphogenetic protein (BMP). Upon ligand binding, ACVR1 forms a complex with a type II receptor, which phosphorylates and activates the type I receptor. The activated receptor then phosphorylates and activates SMAD proteins, which regulate gene expression and control a variety of cellular processes, including cell proliferation, differentiation, and death.
Clinical Significance[edit]
Mutations in the ACVR1 gene cause Fibrodysplasia Ossificans Progressiva (FOP), a rare and disabling genetic condition characterized by progressive ossification of soft tissues, leading to the formation of extra-skeletal bone. Most cases of FOP are caused by a specific mutation in ACVR1 (R206H) that leads to increased BMP signaling and enhanced osteogenic differentiation.
Research[edit]
Research into ACVR1 and its role in FOP has led to the development of potential therapeutic strategies, including the use of retinoic acid receptor gamma (RARγ) agonists and ALK2 kinase inhibitors. These treatments aim to reduce the abnormal bone formation associated with FOP by inhibiting the overactive BMP signaling pathway.
